Immatics inks $58 mln
Immatics, a German cancer immunotherapy company, has closed its Series E financing round at $58 million. The backers included dievini Hopp Biotech holding, Wellington Partners, AT Impf GmbH and Amgen.
4 October 2017•1 min read
Immatics, a German cancer immunotherapy company, has closed its Series E financing round at $58 million. The backers included dievini Hopp Biotech holding, Wellington Partners, AT Impf GmbH and Amgen.
